Two medical imaging techniques, called positron emission tomography (PET) and computed tomography (CT), could be used in combination as a biomarker to predict the effectiveness of antibiotic drug regimens being tested to treat tuberculosis (TB) patients, according to researchers at the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health. With multidrug-resistant tuberculosis (MDR-TB) and extensively drug-resistant tuberculosis (XDR-TB) on the rise worldwide, new biomarkers are needed to determine whether a particular TB drug regimen is effective.
MT Coleman et al. PET/CT imaging reveals a therapeutic response to oxazolidinones in macaques and humans with tuberculosis. Science Translational Medicine DOI:10.1126/scitranslmed.3009500 (2014).
NIAID Director Anthony S. Fauci, M.D., and Clifton E. Barry III, Ph.D, chief of the Tuberculosis Research Section in NIAID's Laboratory of Clinical Infectious Diseases, are available to speak about this research.
To schedule interviews, please contact Emily Mullin, (301) 402-1663, email@example.com.